David Risinger
Stock Analyst at Leerink Partners
(2.97)
# 427
Out of 5,331 analysts
195
Total ratings
60.49%
Success rate
38.20%
Average return
Main Sectors:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Upgrades: Outperform | 762 834 | 604.66 | 37.93% | 8 | Feb 5, 2025 | |
JNJ Johnson & Johnson | Maintains: Outperform | 182 169 | 156.03 | 8.31% | 3 | Jan 23, 2025 | |
ABBV AbbVie | Upgrades: Outperform | 206 | 198.44 | 3.81% | 7 | Nov 22, 2024 | |
BMY Bristol-Myers Squibb | Upgrades: Outperform | 55 73 | 50.48 | 44.61% | 4 | Nov 12, 2024 | |
TECX Tectonic Therapeutic | Maintains: Outperform | 49 69 | 21.68 | 218.27% | 2 | Nov 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 5.81 | 175.39% | 1 | Oct 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 44 | n/a | n/a | 2 | Sep 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 106 153 | 35.34 | 332.94% | 2 | Sep 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 15 10 | 10.38 | -3.66% | 3 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 28 2 | 1.96 | 2.04% | 2 | Jul 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 47 | 21.3 | 120.66% | 1 | Apr 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 267 318 | 280.93 | 13.2% | 4 | Oct 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 11 | 13.65 | -19.41% | 2 | Aug 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 410 458 | 824.15 | -44.43% | 16 | May 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 42 | 61.2 | -31.37% | 3 | Mar 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 374 365 | 500.87 | -27.13% | 3 | Feb 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 81 91 | 103.64 | -12.2% | 3 | Feb 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 49 48 | 24.19 | 98.43% | 14 | Feb 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 8 10 | 11.48 | -12.89% | 4 | Dec 19, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 88 117 | n/a | n/a | 12 | Dec 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 10 | 29.39 | -65.97% | 2 | Jun 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 37 | 9.59 | 285.82% | 2 | Feb 22, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 162 176 | 120.03 | 46.63% | 3 | Apr 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 16 | 8.64 | 85.19% | 1 | Mar 10, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 53 45 | 25.61 | 75.71% | 7 | Mar 5, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 5 7 | n/a | n/a | 8 | Mar 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 22 35 | 5.42 | 545.76% | 4 | Feb 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 41 | 9.75 | 320.51% | 5 | Nov 24, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 167 174 | 157.49 | 10.48% | 9 | Nov 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 51 | 32.95 | 54.78% | 1 | Jul 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 8 | 16.2 | -50.62% | 14 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 18 | n/a | n/a | 12 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 89 | 83.05 | 7.16% | 8 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 16 | 31.82 | -49.72% | 6 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 7.98 | -62.41% | 4 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 156 | n/a | n/a | 8 | Jan 30, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 14 35 | n/a | n/a | 5 | Aug 17, 2018 |